highly reliable monoclonal antibodies...cular, prostate and urothelial cancer as well as in...

HIGHLY RELIABLE MONOCLONAL ANTIBODIES

Unique features of the monoclonal antibodiesAtlas Antibodies are there to help you choose the right monoclonal antibody for your needs. Rather than offering numerous products to the same tar-get, we make sure to select only the most relevant antibodies to each tar-get.

Atlas Antibodies take special care in offering clones recognizing only unique non-overlapping epitopes and/or isotypes. Using the same stringent production process and characteri-zation procedure as for our Triple A Polyclonals, our monoclonal antibod-ies offer outstanding performance in approved applications, together with defined specificity, secured continu-ity and stable supply. In general they also permit higher working dilutions and contribute to more standardized assay procedures.

Antigen SelectionThe Protein Epitope Signature Tag (PrEST) concept gives you antibody performance built in from the start. Using proprietary bioinformatics soft-ware, 50-150 amino acid regions with the lowest possible sequence identity to other human proteins are selected, cloned and recombinantly produced in a tightly controlled set-up.

Clone SelectionFunctional characterization is per-formed on a large number of ELISA positive cell supernatants to select the optimal clones for each applica-tion prior to subcloning and expan-sion of selected Hybridomas.

Epitope MappingClones are epitope-mapped using synthetic overlapping peptides in a bead-based array format for selec-tion of clones with non-overlapping epitopes only.

IsotypingAll our monoclonal antibodies are iso-typed to allow for multiplexing using isotype-specific secondary antibod-ies.

Hybridoma Cell CultivationFor ethical reasons Atlas Antibodies uses only in-vitro methods for the pro-duction scale-up phase thus replac-ing the use of mice for production of ascites fluid.

Antibody CharacterizationThe characterization of Atlas Antibod-ies Monoclonal Antibodies starts with an extensive literature search to se-lect the most relevant and clinically significant tissues to use for immu-nohistochemistry (IHC) characteriza-tion. You will often find more than one tissue type displayed in the IHC appli-cation data in our product catalog. In addition to positive stained tissue we also display a negative control tissue staining and if relevant clinical cancer tissue staining.

The characterization for Western blot (WB) data follows that same work-ing procedure and starts with a pro-found literature search to find the best matching lysate, which can be endog-enous human cell or tissue protein lysates or optionally recombinant full-length human protein lysates.

Each monoclonal antibody is thus supplied with the most relevant char-acterization data for its specific target.

.

Monoclonal Antibodies at Atlas Antibodies

The Anti-VIM (Vimentin) antibody (AMAb90516) shows strong positivity in mesenchymal and lymphoid cells in human rectum using immunohisto-chemical staining.

The Anti-DICER1 antibody (AMAb90737) shows cytoplasmic immunoreactivity in the glandular epi-thelium cells in human uterus using immunohistochemical staining.

The Anti-SIX1 antibody (AMAb90544) shows strong nuclear immunoreactiv-ity in the myocytes in human striated muscle using immunohistochemical staining.

Monoclonal Antibody Development ProgramResearch remains at the heart of At-las Antibodies. We welcome custom-ers to contact us for possible collabo-rations on both existing and future product offerings. One of our collabo-ration programs aims at developing monoclonal antibodies in collabora-tion with our customers.

Atlas Antibodies encourage you to participate in our Monoclonal Anti-body Development Program for hu-man targets. If you are looking for monoclonal antibodies currently not available in our catalog, and if you are interested in developing the antibody together with us, please send in your request to us.

Upon agreement to proceed with a collaboration, Atlas Antibodies will develop and produce the monoclonal antibody using our standardized pro-

cedures. Within this procedure we al-ways epitope map all our clones and this will give you the possible option to obtain multiple clones with unique binding specificity. The selection of the optimal clones will be done in col-laboration with you. Antibodies can either be sent to you for additional characterization in your laboratory or Atlas Antibodies can make the char-acterization at our facilities with our expert input and/or material. Atlas An-tibodies cover all other development costs. If the project results in a com-mercialized product it will be added to Atlas Antibodies Monoclonal prod-uct portfolio and available to you for a special discount price. All our final products will be stained and annotat-ed by the Human Protein Atlas (HPA) project and these results will be avail-able on the HPA web portal.

Benefits of the program Atlas Antibodies take the full develop-ment cost while you get a discounted antibody with proven functionality in your experimental set-up.

For more information and/or requests for participating in the program, you are welcome to contact us at [email protected].

We are looking forward to hearing from you.

Collaboration project for SOX11The mouse monoclonal Anti-SOX11 antibodies AMAb90501 and AMAb90502 were developed in col-laboration with Dr Antonio Martinez (Laboratory of Pathology, Hospi-tal Clínic, University of Barcelona, Spain).

Dr Martinez is involved in the study of aggressive lymphomas, mecha-nisms of transformation, progres-sion and prognostic factors. He has collaborated in the description of transcription factors involved in B-cell development and lymphom-agenesis with special emphasis in those related in late B-cell differenti-ation pathways such as IRF4, IRF8, XBP1 and SOX11. His lab has long expertise in the characterization of antibodies for clinical use in he-matopathology.

SOX11This gene encodes a member of the group C SOX (SRY-related HMG-box) transcription factor fam-ily involved in the regulation of em-bryonic development and in the determination of the cell fate. The encoded protein may act as a tran-scriptional regulator after forming a protein complex with other pro-teins. The protein may function in the developing nervous system and play a role in tumorigenesis and adult neurogenesis. Diseases as-sociated with SOX11 include mantle cell lymphoma (MCL), lymphoblas-tic lymphoma, Burkitt lymphoma and malignant glioma. The diag-nosis of mantle cell lymphoma can be difficult, especially in Cyclin D1 negative cases and the transcrip-tion factor SOX11 may serve as an important diagnostic marker. For this purpose, there is a need of a reliable Anti-SOX11 antibody in the clinical setting.

Tonsil involved by a Classical Mantle cell lympho-ma, cyclin D1 negative in a 50 yo male. SOX11 staining (AMAb90501, clone CL0142; Atlas Anti-bodies).

Lymph node involvement by Classical Mantle cell lymphoma positive for Cyclin D1 in a 64 yo male. SOX11 is expressed in virtually all tumor cells. (AMAb90502, clone CL0143; Atlas Antibodies).

Soldini D et al. Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characteri-zation of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma. Am J Surg Pathol. 2013 Oct 18.

Collaboration project forPLA2R1The PLA2R (PLA2R1) is a trans-membrane receptor belonging to the mannose receptor family and a receptor for the secreted phos-pholipase A2, a lipolytic enzyme that cleaves the fatty acid bond of membrane glycerophospholipids. A common functional feature of this family of receptors is their ability to undergo endocytosis and thus be involved in the internalization of extra-cellular ligands. The PLA2R protein likely exists both in a trans-membranous and a soluble form. The M-type phospholip-ase A2 re-ceptor (PLA2R) has been identified as a major target antigen involved in

idiopathic membranous nephropa-thy in adults.

Our mouse monoclonal Anti-PLA2R1 (AMAb90775) antibody was developed in collaboration with Dr Hanna Debiec.

Dr Hanna Debiec was trained in bio-chemistry, cell biology, and physiol-ogy. She is one of the leaders in the field of membranous nephropathy (MN) and is working as a scientific director in the immunopathology research team of Professor Pierre Ronco. This Research team has made several discoveries on the pathogenesis of MN.

Collaboration project forSCGN, NECAB1 and NE-CAB2The monclonal antibodies Anti-SCGN (AMAb90630), Anti-NECAB1 (AMAb90801) and Anti-NECAB2 (AMAb90808) have been devel-oped in collaboration between Dr Jan Mulder (SciLifeLab Stockholm, Sweden) and Atlas Antibodies.

Dr Mulder´s group performs anti-body based profiling of proteins in the human and rodent nervous sys-tem using biochemical and immuno-fluorescence techniques in combi-nation with automated microscopy. The aim is to quantify and visualize regional, cellular and subcellular distribution of proteins in the devel-oping, healthy and diseased nerv-ous system.

In collaboration with the Human Protein Atlas (HPA) project, utilizing the unique antibody resource cre-ated within the project, they aim to 1) investigate protein distribution in a large portion of the nervous sys-

tem using the smaller rodent brain and 2) identify changes in protein expression and distribution in the human brain affected by neurode-generative disorders.

Shi TJ et al. Secretagogin is expressed in sensory CGRP neurons and in spinal cord of mouse and complements other calcium-binding proteins, with a note on rat and human. Mol Pain 2012 Oct 29;8:80

Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephrop-athy. N Engl J Med 2011 Feb 17;364(7):689-90.

Debiec H et al. Autoantibodies Specific for the Phos-pholipase A(2) Receptor in Recurrent and De Novo Membranous Nephropathy. Am J Transplant 2011 Oct;11(10):2144-52.

IF staining of paraffin embedded kidney biopsy specimen from patient with membranous nephrop-athy using the monoclonal Anti-PLA2R1 antibody AMAb90775.

IF staining of mouse hypothalamus using. Distribu-tion of NECAB1 (green) in the mouse dorsal medial thalamus. The monoclonal Anti-NECAB1 antibody AMAb90801 strongly labels neurons and their pro-cesses in the paraventricular and mediodorsal tha-lamic nuclei. Blue is the nuclear staining Hoechst.

Immunohistochemical staining of human pancreas shows strong cytoplasmic and nuclear immunore-activity in the islets of Langerhans.

RBM3 - A prognostic and treatment predictive biomarker The RNA-binding protein RBM3 has been identified via the Human Pro-tein Atlas as an oncology biomarker through the differential expression pattern observed within several in-vestigated cancers.

In general, the levels of RBM3 ex-pression have been found to have a significant correlation to patient sur-vival in breast, colon, ovarian, testi-cular, prostate and urothelial cancer as well as in malignant melanoma. The monoclonal Anti-RBM3 antibo-dy AMAb90655 has shown excellent specificity in Western blot analysis and is routinely used for staining of formalin fixed paraffin embedded tis-sues in IHC.

A major clinical challenge in urothe-lial cancer is the identification of high-risk patients among those di-agnosed with non-invasive disease. Our data suggests that RBM3 ex-pression analysis could be used as a prognostic factor for better stratification of patients, leading to a more individualized treatment of patients with urothelial cancer. The prognostic significance of RBM3 in urothelial cancer has been confir-

med in several independent cohorts.Our findings indicate that patients whose tumors express high levels of RBM3 could benefit from platinum-based treatment, whereas alterna-tive treatments may be considered for patients having no or low RBM3 expression. In vitro cell-line expe-riments have also demonstrated a role of RBM3 in respect to treatment with platinum-based drugs like cisp-latin. This has been further validated in a colorectal cancer cohort where patients with tumors expressing high levels of RBM3 showed a markedly increased survival upon platinum adjuvant treatment compared to pa-tients receiving no- or non-platinum based adjuvant treatment.

Need for Novel Cancer Biomarkers The microscopic evaluation of stained tissue sections from a tumor remains the gold standard for cancer diag-nosis. However, in order to optimize patient treatment and provide guid-ance for therapeutic intervention of the underlying disease there is often a need for additional tumor stratifica-tion methods.

The analysis of protein expression in cells from a tumor tissue often pro-vides important additional information to the responsible pathologist. Immu-nohistochemistry (IHC) using protein specific antibodies provides a tool to detect the presence, abundance and localization of specific proteins.

With a limited repertoire of protein biomarkers available today there is a clear and unmet clinical need to identi-fy novel sets of biomarkers. The needs are both to provide a more accurate diagnosis and a better assessment of patient prognosis, ultimately leading to a more individualized treatment.

Atlas Antibodies recognize this need for new biomarkers. Together with our research partners in the Human Pro-tein Atlas project we are in a unique position to perform antibody-based biomarker discovery.

Biomarkers for LicensingAtlas Antibodies currently have seve-ral proprietary oncology biomarkers. These are now available for licensing together with the accompanying mo-noclonal antibodies. An overview of a few selected biomarkers is given be-low.

For additional information on licensing of specific biomarkers, or if you would like to know more about Atlas Antibo-dies customized solutions and valida-tion capabilities, please contact us directly at [email protected] or visit our Research Collaborations page (atlasantibodies.com/research/collaborations).

Survival analysis of urothelial cancer patients strati-fied according to RBM3 expression.

Representative nuclear staining of RBM3 in urothe-lial cancer, with no RBM3 expression (A), intermedi-ate RBM3 expression (B) and high RBM3 expression (C) respectively. Immunohistochemistry analysis is performed using the monoclonal Anti-RBM3 antibody AMAb90655.

Related PublicationsEhlén A et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 2010 Aug 20;8:78.

Hjelm B et al. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. 2011 Dec;5(11-12):624-35.

Boman K et al. Decreased expression of RNA-binding motif pro-tein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol. 2013, 13:17.

Oncology Biomarkers

PODXL - An independent factor for poor prognosis and treatment stratificationPodocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associ-ated with aggressive tumor pheno-type and adverse outcome in sev-eral cancer types.

In a number of recently published papers, Larsson et al have demon-strated that membraneous expres-sion of PODXL is associated with unfavourable clinicopathological characteristics and independently predicts a poor prognosis in colo-rectal cancer (CRC). This has been demonstrated in three independent patient cohorts in total comprising more than 1,000 patients. The re-sults clearly demonstrate the poten-tial utility of PODXL as a biomarker for more precise prognostication and treatment stratification in CRC.

Boman et al have investigated the prognostic impact of membraneous PODXL expression in almost 500

cases of urothelial cancer. They con-cluded that PODXL is indeed an in-dependent risk factor for progressive disease and death in patients with urothelial cancer and that this war-rant further studies to fully evaluate the use of PODXL as a biomarker for improved treatment stratification of bladder cancer patients.

SATB2 – A diagnostic biomarker for tumors of colorectal originCell- and cancer-type specific pro-teins are rare. The special AT-rich sequence-binding protein SATB2 has been identified as having a very selective expression pattern. In cells of epithelial lineages, SATB2 is expressed in glandular cells lin-ing the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers. Thus, SATB2 is a promising diagnostic biomarker for tumors of colorectal origin.

In a previously published study by Magnusson et al it was shown, by analyzing more than 1,800 tumor samples, that SATB2 expression is largely preserved in cells of colorect-lal cancer origin. More than 85% of all colorectal cancers showed distinct SATB2 immunostaining and when used in combination with Cytokeratin 20 analysis, SATB2 identified more than 95% of all tumors with colorectal origin.

These promising data suggested that the combination of SATB2 and CK20 should be tested in an unbi-ased clinical study to further validate the initial findings. In a recent pub-lication by Dragomir et al, the ex-pression of SATB2 was analyzed in over 800 consecutive clinical cases for which CK20 immunostaining was considered necessary to obtain a fi-nal diagnosis. In this study, SATB2 showed 93% sensitivity and 77% specificity to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specific-ity increased to 100%. SATB2 thus provides a new and advantageous supplement to current standards for clinical differential diagnosis.

In Atlas Antibodies´ product cata-log, there are five monoclonal Anti-SATB2 antibodies recommended for IHC and WB analysis. Related Publications

Magnusson K et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011 Jul;35(7):937-48.

Dragomir A et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results from a pathology-based clinical prospective study. Am J Clin Pathol. 2013 In press.

C D

A B

Immunohistochemical staining of PODXL protein in colorectal tumor tissue using A) HPA002110, B) AMAb90643, C) AMAb90644 and D) AMAb90667 antibodies.

Kaplan–Meier estimates of 5-year Overall Survival (OS) according to PODXL expression in a urothe-lial cancer patient cohort of 110 individuals.

Immunohistochemical staining of human colorec-tal tumor with Anti-SATB2 antibody (AMAb90635) shows strong nuclear staining in tumor cells.

Related PublicationsLarsson A et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011 Aug 23;105(5):666-72.

Larsson A et al. Validation of podocalyxin-like protein as a bio-marker of poor prognosis in colorectal cancer. BMC Cancer. 2012 Jul 8;12:282.

Boman K et al. Membraneous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br J Cancer. 2013 Jun 11;108(11),

Mouse Monoclonal Antibodies

Anti-ADARProduct Name Anti-ADAR

Product Number AMAb90535

Isotype IgG1

Validated Applications

IHC, WB

Anti-ACSL5Product Name Anti-ACSL5


Isotype IgG1


IHC, WB

Anti-ANLN/Anillin Product Name Anti-ANLN


Isotype IgG1


IHC, WB

Epitope PSKGELSREICLQSQ

Anti-ANXA1/Annexin A1Product Name Anti-ANXA1


Isotype IgG1


IHC, WB

Epitope PQLRRVFQKY

Anti-APOA4Product Name Anti-APOA4


Isotype IgG2a


IHC, WB

Epitope LRQRLAPLAEDVRGN

Anti-AKT1Product Name Anti-AKT1


Isotype IgG1


WB

Epitope FEYLKLLGKGTFGKV

Anti-AKT1Product Name Anti-AKT1


Isotype IgG1


WB

Epitope ILVKEKATGRYYAMK

Anti-ANLN/Anillin Product Name Anti-ANLN


Isotype IgG1


IHC, WB

Epitope LRGRFDKGNIWSAEK



Isotype IgG1


IHC, WB

Epitope EQLRQKLGPHAGDVE



Isotype IgG1


IHC, WB

Epitope GHLSFLEKDL

Anti-ATRXProduct Name Anti-ATRX


Isotype IgG1


IHC

Anti-APOL1Product Name Anti-APOL1


Isotype IgG1


WB

Epitope ESGEQVERVN

Anti-AQP4/Aquaporin 4Product Name Anti-AQP4


Isotype IgG1


IHC, WB

Anti-ARG1/Arginase 1Product Name Anti-ARG1


Isotype IgG1


IHC, WB

Anti-ATAD2Product Name Anti-ATAD2


Isotype IgG1


IHC, WB

Epitope VGDKRSDPEQ

Anti-ATP6AP2/Renin receptorProduct Name Anti-ATP6AP2


Isotype IgG1


IHC



Isotype IgG1


IHC, WB

Epitope AEELKKVAQELEEKL



Isotype IgG1


WB

Epitope GIGKDIRALR

Anti-BRD4Product Name Anti-BRD4


Isotype IgG1


IHC, WB

Epitope PQPAKPQQVIQHHHS

Anti-BRD4Product Name Anti-BRD4


Isotype IgG1


IHC, WB

Epitope EAPSPLMIHSPQMSQ

Anti-CA12

Anti-CD4Product Name Anti-CD4


Isotype IgG1


IHC

Anti-CD45/PTPRCProduct Name Anti-CD45


Isotype IgG1


IHC, WB

Epitope LNLDKNLIKY

Anti-CD45/PTPRCProduct Name Anti-CD45


Isotype IgG2a


IHC, WB

Epitope LNLDKNLIKY

Anti-CHGA/Chromogranin AProduct Name Anti-CHGA


Isotype IgG1


IHC, WB

Epitope HSGFEDELSEVLENQ

Anti-CNDP1Product Name Anti-CNDP1


Isotype IgG1


WB

Epitope DEFVQTLKEWVAIES

Anti-CTCFProduct Name Anti-CTCF


Isotype IgG2a


IHC, WB

Epitope AYENEVSKEG

Anti-CA12Product Name Anti-CA12


Isotype IgG2a


IHC, WB

Epitope HLQHVKYKGQEAFVP

Anti-KIT/CD117Product Name Anti-KIT


Isotype IgG1


WB

Epitope DPGFVKWTFE

Anti-KIT/CD117Product Name Anti-KIT


Isotype IgG1


IHC, WB

Epitope ILDETNENKQNEWIT

Product Name Anti-CA12


Isotype IgG1


IHC, WB

Epitope HLQHVKYKGQEAFVP

Anti-CTCF

Anti-CTCF

Product Name Anti-CTCF


Isotype IgG1


IHC, WB

Epitope NMEEQPINIGELQLV

Product Name Anti-CTCF


Isotype IgG2b


IHC, WB

Epitope TLPLPEGFQV

Anti-EMD/EmerinProduct Name Anti-EMD


Isotype IgG2a


IHC, WB

Epitope DALLYQSKGYNDDYY

Anti-DICER1Product Name Anti-DICER1


Isotype IgG2a


IHC

Anti-DOCK8Product Name Anti-DOCK8


Isotype IgG1


IHC, WB

Anti-DIAPH2Product Name Anti-DIAPH2


Isotype IgG1


IHC, WB

Epitope SLNLSEKEVLDLFEK

Anti-DIAPH2Product Name Anti-DIAPH2


Isotype IgG1


IHC, WB

Epitope IKTLADDVRDRITSF

Anti-EGFR/ERBBProduct Name Anti-EGFR


Isotype IgG1


IHC, WB

Epitope RTDLHAFENL

Anti-EGFR/ERBBProduct Name Anti-EGFR


Isotype IgG1


WB

Epitope DSFTHTPPLD

Anti-EMD/EmerinProduct Name Anti-EMD


Isotype IgG1


IHC, WB

Epitope QSKGYNDDYY

Anti-FABP7Product Name Anti-FABP7


Isotype IgG1


IHC, WB

Anti-FBN1/Fibrillin-1Product Name Anti-FBN1


Isotype IgG2b


IHC, WB

Anti-FBN1/Fibrillin-1Product Name Anti-FBN1


Isotype IgG1


IHC

Anti-FLT1/VEGFR-1Product Name Anti-FLT1


Isotype IgG2b


IHC, WB

Anti-HER2/ERBB2Product Name Anti-HER2


Isotype IgG1


IHC, WB

Anti-FUSProduct Name Anti-FUS


Isotype IgG1


IHC, WB

Anti-GDF15Product Name Anti-GDF15


Isotype IgG1


IHC, WB

Anti-HDAC1Product Name Anti-HDAC1


Isotype IgG1


IHC, WB

Anti-FBLN1/Fibulin 1Product Name Anti-FBLN1


Isotype IgG1


IHC, WB

Anti-FLT1/VEGFR-1Product Name Anti-FLT1


Isotype IgG1


IHC

Anti-IDH1Product Name Anti-IDH1


Isotype IgG2a


IHC, WB

Epitope IEDFAHSSFQMALSK

Anti-MEF2CProduct Name Anti-MEF2C


Isotype IgG1


IHC, WB

Epitope NLLPLAHPSL

Anti-HNF1BProduct Name Anti-HNF1B


Isotype IgG1


IHC, WB

Anti-KDM5BProduct Name Anti-KDM5B


Isotype IgG1


IHC, WB

Epitope DGINSLERKLKRRLE

Anti-MACC1Product Name Anti-MACC1


Isotype IgG1


IHC

Anti-MCL1Product Name Anti-MCL1


Isotype IgG1


IHC, WB

Epitope PEEELDGYEP

Anti-MEF2CProduct Name Anti-MEF2C


Isotype IgG1


IHC, WB

Epitope SNPVSSLGNPNLLPL

Anti-MKI67/Ki67Product Name Anti-MKI67


Isotype IgG1


IHC

Epitope PLSLSTCLFGRGIEC

Anti-MKL2Product Name Anti-MKL2


Isotype IgG1


WB

Epitope FASVSPTVPEFLKTP

Anti-MMP9Product Name Anti-MMP9


Isotype IgG1


IHC, WB

Epitope VPDLGRFQTF



Isotype IgG2b


IHC

Epitope RGESKSLGPALLLLQ

Anti-MRC1Product Name Anti-MRC1


Isotype IgG2a


IHC, WB

Anti-MST1R/MSP receptorProduct Name Anti-MST1R


Isotype IgG1


WB

Anti-MTDH/LYRICProduct Name Anti-MTDH


Isotype IgG1


IHC, WB

Anti-NAPRT1Product Name Anti-NAPRT1


Isotype IgG1


IHC, WB



Isotype IgG1


IHC, WB

Epitope RGESKSLGPALLLLQ

Anti-MTDH/LYRICProduct Name Anti-MTDH


Isotype IgG2a


IHC, WB

Anti-NAPRT1Product Name Anti-NAPRT1


Isotype IgG1


IHC, WB

Epitope PAFFEHLRALDCSEV

Anti-NECAB1Product Name Anti-NECAB1


Isotype IgG1


IHC, WB

Epitope SIQWPGKRSS



Isotype IgG2a


IHC, WB

Epitope SIQWPGKRSS

Anti-PCM1Product Name Anti-PCM1


Isotype IgG1


IHC, WB

Epitope RQRALYALQD

Anti-PBRM1/Polybromo 1Product Name Anti-PBRM1


Isotype IgG1


IHC, WB



Isotype IgG1


IHC

Epitope IGRLESKALWFDLQQ

Anti-NES/NestinProduct Name Anti-NES


Isotype IgG1


IHC, WB

Anti-P4HA2Product Name Anti-P4HA2


Isotype IgG1


IHC, WB



Isotype IgG2b


IHC, WB

Epitope SIQWPGKRSS

Anti-NLRP3/NACHTProduct Name Anti-NLRP3


Isotype IgG1


WB

Anti-OCLN/OccludinProduct Name Anti-OCLN


Isotype IgG2a


IHC, WB

Epitope TSPVDDFRQPRYSSG



Isotype IgG2a


IHC, WB

Epitope NDKRFYPESSYKSTP



Isotype IgG1


IHC, WB

Epitope RYSSGGNFETPSKRA

Anti-PGAM5

Anti-PHGDH/3-PGDHProduct Name Anti-PHGDH


Isotype IgG1


IHC, WB

Anti-PLA2R1/PLA2RProduct Name Anti-PLA2R1


Isotype IgG1


IHC, WB

Epitope KIPVSFEWSN

Anti-PODXL/Podocalyxin Ref 1

Product Name Anti-PODXL


Isotype IgG1


IHC, WB

Epitope IHTKLPAKDVYERLK

Anti-RBM3 Ref 2,3,4,5,6,7,8

Product Name Anti-RBM3


Isotype IgG1


IHC, WB

Anti-RESTProduct Name Anti-REST


Isotype IgG1


IHC

Anti-PLA2R1/PLA2RProduct Name Anti-PLA2R1


Isotype IgG1


IHC, WB

Epitope VKNCEERLFYICKKA

Anti-PODXL/PodocalyxinProduct Name Anti-PODXL


Isotype IgG2a


IHC, WB

Epitope GASDEKLISLICRAV

Anti-PODXL/PodocalyxinProduct Name Anti-PODXL


Isotype IgG2b


IHC, WB

Epitope PAKDVYERLKDKWDE

Anti-RHOT1/MIRO-1Product Name Anti-RHOT1


Isotype IgG1


IHC, WB

Epitope VTSRWIPLIN

Product Name Anti-PGAM5


Isotype IgG1


IHC, WB

Epitope NWDRREPLSLINVRK

Anti-S100A4/CalvasculinProduct Name Anti-S100A4


Isotype IgG1


IHC, WB

Epitope KFKLNKSELKELLTR

Anti-SATB2 Ref 9,10,11,12

Product Name Anti-SATB2


Isotype IgG1


IHC, WB

Epitope LVNLRAMQNFLNLPE

Anti-RUNX2/AML-3Product Name Anti-RUNX2


Isotype IgG1


IHC, WB

Anti-RHOT1/MIRO-1Product Name Anti-RHOT1


Isotype IgG1


IHC

Epitope ERTDKDSRLP

Anti-RNASE7Product Name Anti-RNASE7


Isotype IgG2a


IHC, WB

Epitope KGMTSSQWFKIQHMQ

Anti-RNASE7Product Name Anti-RNASE7


Isotype IgG1


IHC

Epitope LTMCKLTSGKYPNCR

Anti-RUNX2/AML-3Product Name Anti-RUNX2


Isotype IgG2a


IHC



Isotype IgG2b


IHC, WB

Epitope CNEFFEGFPDKQPRKK



Isotype IgG1


IHC, WB

Epitope CNEFFEGFPD

Anti-SATB2Product Name Anti-SATB2


Isotype IgG2a


IHC, WB

Epitope KCQEFGRWYKKYKKI

Anti-SCGN/Secretagogin Ref 13

Product Name Anti-SCGN


Isotype IgG1


IHC, WB

Anti-SDHBProduct Name Anti-SDHB


Isotype IgG2a


IHC, WB

Anti-SIX1Product Name Anti-SIX1


Isotype IgG1


IHC, WB

Anti-SLC22A2/OCT2Product Name Anti-SLC22A2


Isotype IgG1


IHC

Epitope KNAEAMRIIKHIAKK



Isotype IgG1


IHC, WB

Epitope SLGKTNEQSPHSQIH



Isotype IgG1


IHC, WB

Epitope KCQEFGRWYKKYKKI



Isotype IgG1


IHC, WB

Epitope HSTPIRNQVPALQPI

Anti-SCGN/SecretagoginProduct Name Anti-SCGN


Isotype IgG2a


IHC



Isotype IgG1


IHC, WB

Epitope EEREKLDGLYECILC



Isotype IgG1


IHC, WB

Epitope RLAKLQDPFS

Anti-SLC22A2/OCT2Product Name Anti-SLC22A2


Isotype IgG2b


IHC

Epitope KNAEAMRIIKHIAKK

Anti-SLC27A5/BACSProduct Name Anti-SLC27A5


Isotype IgG1


IHC, WB

Epitope RCFYLSHTSP

Anti-SOX9Product Name Anti-SOX9


Isotype IgG2a


IHC, WB

Epitope SQRTHIKTEQLSPSH

Anti-STX7/Syntaxin-7Product Name Anti-STX7


Isotype IgG1


IHC, WB



Isotype IgG1


IHC, WB

Epitope ESLEEILPKL



Isotype IgG1


IHC, WB

Epitope SHPVPADLRA

Anti-SOX11Product Name Anti-SOX11


Isotype IgG2a


IHC, WB

Epitope IPFIREAERL

Anti-SOX11 Ref 14

Product Name Anti-SOX11


Isotype IgG2a


IHC, WB

Epitope IPFIREAERL

Anti-STAT3 Product Name Anti-STAT3


Isotype IgG1


IHC, WB

Epitope TKFICVTPTTCSNTI

Anti-STAT3 Product Name Anti-STAT3


Isotype IgG1


IHC, WB

Epitope TNILVSPLVY

Anti-TET1Product Name Anti-TET1


Isotype IgG1


IHC

Anti-TG/ThyroglobulinProduct Name Anti-TG


Isotype IgG2b


IHC, WB

Anti-TSPAN7/Tetraspanin-7Product Name Anti-TSPAN7


Isotype IgG1


IHC, WB

Epitope NDERSRAVDHVQRSL

Anti-TSPAN7/Tetraspanin-7Product Name Anti-TSPAN7


Isotype IgG1


IHC

Epitope TDCNPQDLHNLTVAA

Anti-TTR/TransthyretinProduct Name Anti-TTR


Isotype IgG1


IHC, WB

Anti-USP46Product Name Anti-USP46


Isotype IgG2b


WB

Anti-USP46Product Name Anti-USP46


Isotype IgG2a


WB

Anti-VANGL1Product Name Anti-VANGL1


Isotype IgG1


WB

Anti-THY1/CD90Product Name Anti-THY1


Isotype IgG2b


IHC, WB

Epitope ACLVDQSLRLDCRHE

Anti-THY1/CD90Product Name Anti-THY1


Isotype IgG1


IHC, WB

Epitope ACLVDQSLRLDCRHE

Anti-VIM/VimentinProduct Name Anti-VIM


Isotype IgG1


IHC, WB

Anti-WWTR1Product Name Anti-WWTR1


Isotype IgG1


WB

Anti-ZEB1Product Name Anti-ZEB1


Isotype IgG1


IHC, WB

Anti-ZNF703Product Name Anti-ZNF703


Isotype IgG1


IHC

Epitope PGDKAGFRVP

Anti-WHSC1Product Name Anti-WHSC1


Isotype IgG1


IHC

Epitope RVFNGEPGAHDAKLR

Anti-WHSC1Product Name Anti-WHSC1


Isotype IgG2b


IHC, WB

Epitope ALPFIPADKL

Anti-WWTR1Product Name Anti-WWTR1


Isotype IgG1


IHC, WB

Epitope SSWRKKILPESFFKE

1. Boman K, Larsson AH, Segersten U, Kuteeva E, Johannesson H, Nodin B, Eberhard J, Uhlén M, Malmström PU, Jirström K.Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.Br J Cancer. 2013 Jun 11;108(11):2321-8.

2. Ehlén A, Brennan DJ, Nodin B, O’Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström KExpression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.J Transl Med 2010 Aug 20;8:78

3. Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström KHigh RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease pro-gression.Diagn Pathol 2011 Sep 28;6:91

4. Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström KHigh MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanomaDiagn Pathol 782. Epub 2012 Jul 17.

5. Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström KLow RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.J Transl Med 2011 Jul 21;9:114

6. Ehlén Å, Nodin B, Rexhepaj E, Brändstedt J, Uhlén M, Alvarado-Kristensson M, Pontén F, Brennan DJ, Jirström KRBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.Transl Oncol 2011 Aug;4(4):212-21

7. Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson LB, Påhlman S, Jirström K, Uhlen MHigh nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.Proteomics Clin Appl 2011 Dec;5(11-12):624-35

8. Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström PU.Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial blad-der cancer.BMC Urol. 2013 Apr 8;13:17.

9. Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlén M, Ericson Lindquist K, Jirström KA cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.Br J Cancer 2012 Feb 28;106(5):931-8

10. Kiflemariam S, Andersson S, Asplund A, Pontén F, Sjöblom TScalable in situ hybridization on tissue arrays for validation of novel cancer and tissue-specific biomarkers.PLoS One 2012;7(3):e32927

11. Rockberg J, Löfblom J, Hjelm B, Uhlén M, Ståhl SEpitope mapping of antibodies using bacterial surface display.Nat Methods 2008 Dec;5(12):1039-45

12. Dragomir A, de Wit M, Johansson C, Uhlén M, Pontén F.The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results from a pathology-based clinical prospective study.American Journal of Clinical Pathology 2013 Accepted Oct

13. Shi TJ, Xiang Q, Zhang MD, Tortoriello G, Hammarberg H, Mulder J, Fried K, Wagner L, Josephson A, Uhlén M, Harkany T, Hökfelt T.Secretagogin is expressed in sensory CGRP neurons and in spinal cord of mouse and complements other calcium-binding proteins, with a note on rat and human.Mol Pain 2012 Oct 29;8:80

14. Soldini D, Valera A, Solé C, Palomero J, Amador V, Martin-Subero JI, Ribera-Cortada I, Royo C, Salaverria I, Beà S, Gon-zalvo E, Johannesson H, Herrera M, Colomo L, Martinez A, Campo E.Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characterization of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma.Am J Surg Pathol. 2013 Oct 18.

REFERENCES

Atlas Antibodies ABAlbaNova University CenterSE-106 91 Stockholm, Swedenatlasantibodies.com

Phone +46(0)8 54 59 58 50Fax +46(0)8 54 59 58 [email protected]@atlasantibodies.com

atlasantibodies.comOur website provides you with easy access to all characterization data, and online ordering via our web shop. You can also send your order to [email protected].

Or send an e-mail to [email protected] to discuss any matters regarding use of antibodies.You’ll find we’re Totally Human.

highly reliable monoclonal antibodies...cular, prostate and urothelial cancer as well as in...

Documents